Journal
ACTA NEUROLOGICA SCANDINAVICA
Volume 145, Issue 2, Pages 193-199Publisher
WILEY
DOI: 10.1111/ane.13533
Keywords
chronic pain; greater occipital nerve neuralgia; headache; occipital neuralgia; onabotulinum toxin type A
Categories
Ask authors/readers for more resources
The study found that onabotulinum toxin type A is a safe and effective treatment for patients with refractory greater occipital nerve neuralgia, significantly reducing pain severity and frequency without any noticeable side effects.
Objectives To determine the effectiveness of botulinum toxin in a sample of patients diagnosed with greater occipital nerve neuralgia. Material and Methods Twenty-nine patients (28 females, 1 male) were treated for greater occipital nerve neuralgia with onabotulinum toxin type A; the Visual Analog Pain Scale was used to determine pain severity at treatment and again 12 weeks after application. Results Average doses of onabotulinum toxin type A of 18.66 +/- 6.44 U per nerve and 35.96 +/- 12.89 U per patient were utilized. Average pain severity among the sample was 9.81 +/- 0.89 prior to botulinum toxin application and 3.68 +/- 2.31 points (p<0.0001) twelve weeks after application. Pain frequency decreased from 29.93 +/- 0.37 to 12.17 +/- 11.05 days with pain per month (p<0.0001). Six patients reported absence of pain after application (p=0.023). Dose did not correlate with the degree of clinical response observed, and no side effects were reported. Conclusion Our findings suggest onabotulinum toxin type A is a safe and effective treatment alternative for patients suffering from refractory greater occipital nerve neuralgia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available